Women's Health Initiative best practices comparison guide

This assignment has a hidden dependency and everything else waits on it: you must select a disorder from the Women's Health Initiative and then find a current research article on that same disorder. Choose the disorder first, and choose it for the strength of the WHI's own findings on it rather than for personal interest, because instruction three asks you to compare the two sets of best practices and that comparison needs both ends to be substantial. The WHI has clear findings on cardiovascular disease, breast cancer, fracture, stroke and colorectal cancer, and thin ones elsewhere. Then find the current article. Both selections have to be named explicitly in the paper, because three of the five instructions refer to the article you selected, and a marker cannot check a comparison whose second term was never identified.

The temporal gap is the analytical opportunity here and most papers miss it entirely. The Women's Health Initiative's hormone therapy trials ran into the early 2000s and the results were published across the two decades that followed. Anything called a current best practice was formulated with those findings already in the literature. So the comparison instruction three asks for is not a comparison between an old wrong answer and a new right one. It is a comparison between what a large randomised trial could show at the time and what has been established since, often through evidence of a different kind. Framing it that way lets you say something more useful than that guidelines change, and it protects you from the retrospective condescension that marks out a weak comparison essay. It also gives instruction four something to work with, because a change driven by new evidence has different consequences from a change driven by a reinterpretation of old evidence.

Colorectal cancer illustrates why the comparison is worth making carefully, and it is a strong disorder to choose. The WHI's estrogen plus progestin trial reported substantially fewer colorectal cancer diagnoses in the treatment group, with a hazard ratio around 0.63, which reads as a large protective effect. But the cancers that were diagnosed in that group were found at a more advanced stage, and the estrogen-alone trial showed no effect at all. So a single trial produced a headline finding, a complication that undercuts it, and an arm that failed to replicate it. That is the shape of most real evidence, and a paper that reports all three parts is doing what instruction three asks. A paper that reports only the hazard ratio has quoted a finding rather than evaluated it, and the difference between those two things is most of what this assignment is assessing.

Instruction two asks for current best practices in assessing and managing the disorder, and assessment usually carries the sharper change. For colorectal cancer the concrete example is screening age: the United States Preventive Services Task Force lowered the recommended start of screening from 50 to 45 in 2021, a grade B recommendation for ages 45 to 49 alongside the existing grade A for 50 to 75. That is a specific, dated, gradable change you can point at, and it did not come from hormone therapy evidence at all. It came from rising incidence in younger adults. Notice what that does to your comparison: the most important change in practice for this disorder since the WHI has nothing to do with what the WHI was testing. Say so, because it is exactly the kind of observation instruction four is inviting.

Instruction four asks how the differences might impact women's health, and it wants consequences rather than sentiment. Work in both directions. A lowered screening age reaches disease earlier in a population that was previously not screened at all, which changes stage at diagnosis and therefore survival, and it also increases colonoscopy demand and the harms that come with a larger screened population. Withdrawing a therapy that appeared protective for one outcome removes that protection while removing the harms that caused it to be withdrawn. Women's health is affected by both movements, and quantifying even one of them, in incidence or in stage or in absolute risk, converts an assertion into an argument. Vague statements about improved outcomes are the commonest weakness in answers to this instruction, and they are easy to avoid: every claim you make here should be able to finish the sentence for how many women, and by how much.

Instruction five asks for a position with evidence-based support, and the honest position is usually conditional. Should the current best practices in your chosen article be used in clinical practice? Answer yes, no or yes-with-conditions in a single sentence, then defend it on the strength of the evidence rather than on its recency. The questions worth asking out loud are whether the article's population matches the patients you would apply it to, whether the recommendation rests on trial evidence or on observational data, whether harms were measured alongside benefits, and whether a guideline body has adopted it. A recommendation supported by one observational study and not yet in any guideline is not ready for practice, and saying so is a stronger answer than endorsing it because it is new. Name the piece of evidence that would change your answer, since that is what distinguishes a considered position from a preference.